InvestorsHub Logo
Followers 26
Posts 2634
Boards Moderated 0
Alias Born 10/23/2003

Re: None

Tuesday, 07/21/2020 10:33:04 AM

Tuesday, July 21, 2020 10:33:04 AM

Post# of 309
MESO - ARDS review August 13th looking for approval in Sept.

I would think we should also see some results from phase 3 trial in Covid which started enrollment in May. Reduced usage of ventilators may have slowed this trial. 83% survival rate 10/12 patients on ventilators vs 9% come of ventilators with standard treatments.

July 5, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that an expanded access protocol (EAP) has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C). Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MESO News